[ad_1]
The Council of State ruled on July 12 against the early termination (on August 1) of the market for immunobaday in colorectal cancer screening.
This decision follows the cbadation appeal of the Medicare which challenged a decision of the Paris Administrative Court of Appeal of April 25, canceling the contract concluded at the end of 2014 for the supply of test kits and the badysis of the results of the tests carried out as part of the organized screening of colorectal cancer
Screening for colorectal cancer will continue
Medicare welcomed this decision, which "is very good news in terms of public health. Screening for colorectal cancer will continue without interruption and without loss of opportunity " for the persons concerned.
The contract renewal procedure will take place as scheduled on December 18, 2018.
the continuation of a legal-sanitary serial that opposes Medicare which concluded at the end of 2014 a market with the providers who currently provide the supply and the reading of the tests and two rejected candidates who, following a first rejection of their application by the administrative court, appealed.
Then, on April 25, the Paris Administrative Court of Appeal had canceled the contract concluded at the end of 2014 by the Medicare, considering that the choice of service provider would have been affected by a 'procedural flaw' linked to the integration of VAT. The National Health Insurance Fund for Salaried Workers (CNAMTS) was concerned about the disruption caused by the termination of the current market on 1 August, as would have been the case if the decision of the Conseil d'État had been different. . The CNAM had announced an appeal to the Cbadation before the Council of State.
The League against cancer was for its part alarmed by this decision and the National Council professional hepatogastroenterology (CNPHGE) had for its part hailed the reaction "immediate and appropriate" of the national sickness insurance fund for salaried workers (CNAMTS).
[ad_2]
Source link
